1. Home
  2. ICUCW vs SBAC Comparison

ICUCW vs SBAC Comparison

Compare ICUCW & SBAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ICUCW
  • SBAC
  • Stock Information
  • Founded
  • ICUCW N/A
  • SBAC 1989
  • Country
  • ICUCW United States
  • SBAC United States
  • Employees
  • ICUCW 12
  • SBAC N/A
  • Industry
  • ICUCW Biotechnology: Pharmaceutical Preparations
  • SBAC Real Estate Investment Trusts
  • Sector
  • ICUCW Health Care
  • SBAC Real Estate
  • Exchange
  • ICUCW Nasdaq
  • SBAC Nasdaq
  • Market Cap
  • ICUCW N/A
  • SBAC N/A
  • IPO Year
  • ICUCW 2021
  • SBAC 1999
  • Fundamental
  • Price
  • ICUCW $0.04
  • SBAC $228.36
  • Analyst Decision
  • ICUCW
  • SBAC Buy
  • Analyst Count
  • ICUCW 0
  • SBAC 14
  • Target Price
  • ICUCW N/A
  • SBAC $257.07
  • AVG Volume (30 Days)
  • ICUCW N/A
  • SBAC 852.0K
  • Earning Date
  • ICUCW N/A
  • SBAC 10-28-2024
  • Dividend Yield
  • ICUCW N/A
  • SBAC 1.72%
  • EPS Growth
  • ICUCW N/A
  • SBAC 39.29
  • EPS
  • ICUCW N/A
  • SBAC 6.34
  • Revenue
  • ICUCW N/A
  • SBAC $2,660,958,000.00
  • Revenue This Year
  • ICUCW N/A
  • SBAC N/A
  • Revenue Next Year
  • ICUCW N/A
  • SBAC $2.79
  • P/E Ratio
  • ICUCW N/A
  • SBAC $36.06
  • Revenue Growth
  • ICUCW N/A
  • SBAC N/A
  • 52 Week Low
  • ICUCW N/A
  • SBAC $183.64
  • 52 Week High
  • ICUCW N/A
  • SBAC $258.76
  • Technical
  • Relative Strength Index (RSI)
  • ICUCW N/A
  • SBAC 38.41
  • Support Level
  • ICUCW N/A
  • SBAC $225.21
  • Resistance Level
  • ICUCW N/A
  • SBAC $247.04
  • Average True Range (ATR)
  • ICUCW 0.00
  • SBAC 5.21
  • MACD
  • ICUCW 0.00
  • SBAC -2.04
  • Stochastic Oscillator
  • ICUCW 0.00
  • SBAC 13.34

About ICUCW SeaStar Medical Holding Corporation Warrant

SeaStar Medical Holding Corp is a medical technology company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs. It is developing and commercializing extracorporeal therapies that target the effector cells that drive systemic inflammation, causing direct tissue damage and secreting a range of pro-inflammatory cytokines that initiate and propagate imbalanced immune responses.

Share on Social Networks: